Trial Profile
A phase III trial of capmatinib in patients with non-small cell lung cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2019
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 22 Oct 2019 According to an Novartis Media release, the company expects to submit a new drug application to the FDA for capmatinib as a treatment for patients with advanced NSCLC harboring a MET mutation in Q4 2019.
- 03 Jun 2019 According to an Incyte Corporation Media release, Novartis expects to submit a new drug application to the FDA for capmatinib as a treatment for patients with advanced NSCLC harboring a MET mutation in 2019.
- 14 May 2018 New trial record